- Home
- BFST vs ANAB Comparison
BFST vs ANAB Comparison
Compare BFST & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- ANAB
- Stock Information
- Founded
- BFST 2006
- ANAB 2005
- Country
- BFST United States
- ANAB United States
- Employees
- BFST N/A
- ANAB N/A
- Industry
- BFST Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- ANAB Health Care
- Exchange
- BFST Nasdaq
- ANAB Nasdaq
- Market Cap
- BFST 838.4M
- ANAB 759.5M
- IPO Year
- BFST 2018
- ANAB 2017
- Fundamental
- Price
- BFST $25.94
- ANAB $14.55
- Analyst Decision
- BFST Buy
- ANAB Buy
- Analyst Count
- BFST 2
- ANAB 11
- Target Price
- BFST $28.00
- ANAB $42.67
- AVG Volume (30 Days)
- BFST 130.2K
- ANAB 809.3K
- Earning Date
- BFST 01-21-2025
- ANAB 11-05-2024
- Dividend Yield
- BFST 2.16%
- ANAB N/A
- EPS Growth
- BFST N/A
- ANAB N/A
- EPS
- BFST 2.32
- ANAB N/A
- Revenue
- BFST $249,883,000.00
- ANAB $57,172,000.00
- Revenue This Year
- BFST N/A
- ANAB $233.68
- Revenue Next Year
- BFST $18.42
- ANAB N/A
- P/E Ratio
- BFST $11.18
- ANAB N/A
- Revenue Growth
- BFST 1.14
- ANAB 282.17
- 52 Week Low
- BFST $18.97
- ANAB $14.20
- 52 Week High
- BFST $30.30
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- BFST 35.06
- ANAB 30.98
- Support Level
- BFST $25.36
- ANAB $15.11
- Resistance Level
- BFST $29.03
- ANAB $16.74
- Average True Range (ATR)
- BFST 0.79
- ANAB 1.94
- MACD
- BFST -0.38
- ANAB -0.52
- Stochastic Oscillator
- BFST 15.67
- ANAB 3.00
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).